Emtricitabine
- Generic Name
- Emtricitabine
- Brand Names
- Atripla, Biktarvy, Complera, Descovy, Emtriva, Genvoya, Odefsey, Stribild, Truvada
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10FN3O3S
- CAS Number
- 143491-57-0
- Unique Ingredient Identifier
- G70B4ETF4S
- Background
Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) indicated for the treatment of HIV infection in adults or combined with tenofovir alafenamide for the prevention of HIV-1 infection in high risk adolescents and adults. Emtricitabine is a cytidine analogue. The drug works by inhibiting HIV reverse transcriptase, preventing transcription of HIV RNA to DNA.
Emtricitabine was granted FDA approval on 2 July 2003.
- Indication
Emtricitabine is indicated in combination with other medications for the treatment of HIV-1 infections; treatment of HIV-1 infections in pediatric patients 25-35kg, treatment of HIV-1 infections in adult patients ≥35kg, for pre exposure prophylaxis of HIV-1 in adolescent and adult patients excluding those who have receptive vaginal sex; treatment of HIV-1 infections in pediatric and adult patients ≥17kg, pre exposure prophylaxis in adolescents and adults ≥35kg; treatment of HIV-1 in patients ≥12 years and ≥35kg; treatment of HIV-1 in patients weighing ≥35kg; treatment of HIV-1 in patients weighing ≥25kg; and treatment of HIV-1 in patients weighing ≥40kg.
- Associated Conditions
- HIV Transmission, Human Immunodeficiency Virus (HIV) Infections, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Pre-Exposure Prophylaxis (PrEP)
Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Target Recruit Count
- 390
- Registration Number
- NCT00002416
- Locations
- 🇺🇸
Dr Robert Wallace, St. Petersburg, Florida, United States
🇺🇸North Shore Univ Hosp, Great Neck, New York, United States
A Study of HIV-Disease Development in Aging
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 90
- Registration Number
- NCT00006144
- Locations
- 🇺🇸
Santa Clara Valley Med. Ctr., San Jose, California, United States
🇺🇸Mt. Sinai Med. Ctr. A0404 CRS, New York, New York, United States
🇺🇸Columbia Univ., HIV Prevention and Treatment Medical Ctr., New York, New York, United States
The Safety and Effectiveness of 524W91
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Glaxo Wellcome
- Target Recruit Count
- 18
- Registration Number
- NCT00002335
- Locations
- 🇺🇸
ViRx Inc, San Francisco, California, United States
A Comparison of Emtricitabine and Stavudine Used With Didanosine Plus Efavirenz in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Registration Number
- NCT00006208
- Locations
- 🇺🇸
East Bay Clinical Trial Ctr, Concord, California, United States
🇺🇸Orange Coast Med Group, Newport Beach, California, United States
🇺🇸Health Positive, Safety Harbor, Florida, United States
A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Registration Number
- NCT00002362
- Locations
- 🇺🇸
Northstar Med Clinic, Chicago, Illinois, United States
🇺🇸Houston Clinical Research Network, Houston, Texas, United States
🇺🇸Univ of Texas / Med School at Houston, Houston, Texas, United States
Emtricitabine Given Once A Day With Other Anti-HIV Drugs in Children With HIV
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Triangle Pharmaceuticals
- Target Recruit Count
- 100
- Registration Number
- NCT00017992
- Locations
- 🇺🇸
USC School of Medicine / LA County Med Ctr, Los Angeles, California, United States
🇺🇸Univ of Miami, Miami, Florida, United States
🇲🇽Instituto Mexicano de Investigacion Clinica, Col Roma, Mexico
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.